Olympus Supports Dissemination of Endoscopic Procedures for Colorectal Cancer in Russia

TOKYO, Feb 4, 2021 – (ACN Newswire) – Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has been selected(1) by Japan's Ministry of Health, Labour and Welfare (MHLW) to implement the Japan-Russia Medical Cooperation Promotion Project in the field of endoscopy for the fiscal year ending March, 2021. Under the project, Olympus will promulgate gastrointestinal endoscopic/laparoscopic techniques in support of a five-year oncology plan launched by the Russian government in 2019.(2)

As part of the project, Olympus will facilitate online training programs for gastrointestinal endoscopic/laparoscopic techniques taught by Japanese oncology specialists for Russian endoscopists and oncologists. The bilateral project is being carried out in cooperation with Russia's two premier cancer centers, the N. N. Blokhin Cancer Research Center and the P. Hertsen Moscow Oncology Research Institute branch of the Russian National Medical Research Radiological Centre (NMRRC) as well as Asian Medical Education and Training Support (AMETS).(3) As part of the project's initiatives, Olympus commits to disseminate Japan's world-leading technologies for early diagnosis and treatment in Russia, contributing to the improvement of oncology treatment and research in the region.

Objectives of the MHLW's Japan-Russia Medical Cooperation Promotion Project in the Field of Endoscopy (April 2020 – March 2021):

1. To help advance the Russian government's oncology plan by implementing cancer educational activities for facilities and doctors specializing in that branch of medicine. These activities will take place primarily at Russia's two premier cancer centers, the N. N. Blokhin Cancer Research Center and the P. Hertsen Moscow Oncology Research Institute within the NMRRC.

2. To provide opportunities for training and knowledge sharing on the latest medical technologies by Japanese physicians, contributing to the improvement of gastrointestinal cancer measures, from diagnosis to treatment, particularly for colorectal cancer.

Program activities were unveiled at the Japan-Russia Symposium on Colorectal Cancer Management and at the Signing Ceremony of the Memorandum of Cooperation among AMETS and the two Russian cancer centers, which were held on January 19. The signing ceremony was attended by Japanese and Russian government officials, including Mr. Sergey Muraviev, Director-General, International Cooperation and Public Relations Bureau, Ministry of Health of the Russian Federation, Dr. Teiji Takei, MHLW Assistant Minister for Global Health and Welfare, and Mr. Takeshi Matsunaga, Embassy of Japan in Russia. In addition, 1167 healthcare professionals from all over Russia attended the symposium virtually.

Supported by the MHLW since 2017, Olympus has provided its endoscopic systems for the Endoscopic Training Center at Pirogov Russian National Research Medical University, in addition to supporting training activities with Japanese physicians serving as instructors. The Japan-Russia Medical Cooperation Promotion Project is one of such initiatives by Olympus that MHLW has supported. Moving forward, Olympus will continue to assist with the training of Russian endoscopists, aiming to spread the application of endoscopic diagnosis, treatment and surgery.

(1) Selection was made in June, 2020
(2) Preventive program centered around cancers in the Russian government's national "Healthcare project" that aims to reform its healthcare system. The program, which is promoted by the directors from the two major cancer centers mentioned above, targets an early cancer detection rate of 63% or greater, 5-year survival rate of 60% or greater, and a mortality rate of 17.3% or less. Colorectal cancer is currently the second most prevalent type of cancer in Russia.
(3) A general incorporated institution whose mission is to help spread access to Japan's world-class endoscopy and other medical technologies throughout Asia by providing human resource training support and medical-related education, and by contributing to the development of academic research. (Chairman: Seigo Kitano, President of Oita University)

For questions or additional information, please contact:
Europe, Middle East and Africa (EMEA)
Matthias Gengenbach
+49 4023773 5867
matthias.gengenbach@olympus-europa.com

Japan and Asia Pacific
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Olympus launches comprehensive global educational platform for healthcare professionals

Tokyo / Hamburg, Feb 1, 2021 – (ACN Newswire) – Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the launch of a new comprehensive educational platform designed to provide healthcare professionals (HCPs) all over the world with learning opportunities and training to put their skills into practice and keep them performing at their best.





The "Olympus Continuum" (www.olympuscontinuum.com) platform will empower HCPs at every stage of their career with innovative, premium education and specialized training experiences. The platform builds on the existing Olympus training program, which trains more than 25,000 HCPs annually over 1,400 courses.

Chief Medical Officer, Ross D. Segan, MD, MBA, FACS, said: "Healthcare professionals work in a variety of settings and have a multitude of needs–and their expectations for training courses have evolved well past traditional skills-based learning. Our new platform connects the continuum of care with the continuum of learning. A truly blended experience, Olympus Continuum maximizes digital self-guided pre-learning, direct in-person training, and post-learning collaboration to support healthcare professional across every stage of their career and to improve patient outcome."

HCPs using the "Olympus Continuum" platform will enjoy the following benefits:

– Comprehensive platform programs covering basic to advanced levels: The Olympus global professional education strategy is to establish a continuum of blended learning that takes HCPs from basic to advanced, providing more educational opportunities/experiences and increasing accessibility through the utilization of technology. Hands-on courses will be provided in our 15 dedicated Olympus training labs, as well as hospitals and other labs all over the world.

– Beneficial for remote areas, including emerging countries: In some emerging countries and hard-to-reach areas, it has been difficult for HCPs to receive training or enroll in educational programs because of limited course offerings and large geographical distances. "Olympus Continuum" is a globalized and comprehensive platform of training and education experiences led by healthcare experts from around the world.

– Effective platform that fits well with current conditions created by the COVID-19 pandemic: There was growing demand from healthcare professionals for on-demand, digitally-enabled virtual training and this has increased further during the current COVID-19 pandemic. This new platform exactly meets this demand and provides an excellent combination of virtual and on-site training.

Learning opportunities include hands-on courses, online learning, lectures and workshops, peer-to-peer training, accredited continuing education and on-demand learning.* To learn more about
Olympus Continuum, visit www.olympuscontinuum.com

*Implementation will vary from region to region given market environments.

About Olympus Continuum

Olympus Continuum is a newly launched educational platform for healthcare professionals that will bring the benefits of digitally-enabled learning to remote regions, as well as those impacted by COVID-19. Basic and advanced training for healthcare professionals will be provided through Olympus training centers and hospitals all over the world.

About Olympus

Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries. Olympus' Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments. For more information, visit https://www.olympus-global.com/.

For questions or additional information, please contact:
Europe, Middle East and Africa
Matthias Gengenbach
+49 4023773 5867
matthias.gengenbach@olympus-europa.com

Japan and Asia Pacific
Yuka Horimoto
+81-90-2490-1071
yuka_horimoto@ot.olympus.co.jp

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Olympus to Acquire Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities

Tokyo / Hamburg, Jan 28, 2021 – (ACN Newswire) – Olympus Corporation (Olympus – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (Quest – CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities.

Headquartered in the Netherlands, Quest offers advanced fluorescence imaging systems (FIS) for the medical field, enabling more surgical endoscopy capabilities, compared to conventional imaging technologies.

Fluorescence imaging refers to special light imaging technologies that utilize the properties of fluorescent dyes directed to specific anatomical structures. By using targeted dyes, in combination with specific light wavelengths, tissues or lesions that are nearly invisible under normal white light become visible. Olympus' existing laparoscopic imaging system, VISERA ELITE II, is already equipped with fluorescence imaging technology. VISERA ELITE II uses near-infrared light to identify blood vessels or lymph nodes under the surface tissues, aiming to assist surgeons in performing safer procedures with lower complication risks. The Quest technology acquired is intended to expand opportunities for Olympus in this field.

Making the Invisible Visible

Quest offers innovative technologies for multi-spectral imaging and imaging systems for medical applications, ranging from fluorescence imaging to photodynamic therapy. The acquisition strengthens Olympus' position as a world leader in medical imaging solutions, and delivers innovative capabilities (including 3D and 4K imaging) to surgeons, to "make the invisible visible."

Quest's lead product line is the Quest Spectrum Fluorescence Imaging System, which enables fluorescence-guided surgery for open and minimally invasive procedures. Kanichi Matsumoto, global head of Surgical Endoscopy at Olympus, said: "We are delighted to incorporate Quest's advanced FIS capabilities into our comprehensive medical imaging portfolio. The combination of the Quest Spectrum product line's leading FIS technologies with Olympus' existing laparoscopic imaging system VISERA ELITE II will enable Olympus to offer surgeons a wide range of high quality fluorescence imaging solutions."

New Applications and Market Growth

The global market for FIS devices is expected to grow at a compounding annual rate of more than 12%, from around US$310 million in 2018 to over US$827 million in 2027*. Increasing demand for minimally invasive procedures and reconstructive surgery is helping to drive FIS growth worldwide. Furthermore, application of the FIS technology is expected to expand over the coming years, as additional fluorescent dyes are paired with targeted antibodies. Among other applications, molecular imaging will allow healthcare professionals to visualize cancerous lesions in vivo and perform cancer surgery in unprecedented ways, potentially lowering recurrence rates.

Quest also works with biotechnology companies that are developing next-generation molecular imaging dyes. These innovative dyes may enable Quest's technology to advance diagnostic opportunities in fluorescence-guided cancer surgery.

*Source: Transparency Market Research; Near-Infrared Fluorescence Imaging System Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2019-2027.

About Quest

Quest Photonic Devices B.V. is a multispectral imaging leader and focuses on the medical markets of fluorescence image-guided surgery and cancer-targeted probes. Quest's next generation Spectrum Florescence Imaging System has the ability to "see through tissue" with enhanced sensitivity, capable of accessing otherwise inaccessible information to aid the surgeon in improving clinical outcomes.

About Olympus' Medical business

As a leading medical technology company, Olympus' Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.

For questions or additional information, please contact:

Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com

Japan and Asia Pacific
Yuka Horimoto
+81-90-2490-1071
yuka_horimoto@ot.olympus.co.jp

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

New benchmark set to deliver optimal osteoporosis care throughout Asia Pacific

The Asia Pacific Consortium on Osteoporosis (APCO) has today (Thursday, January 28, 2021) launched the first pan-Asia Pacific clinical practice standards for the screening, diagnosis, and management of osteoporosis, targeting a broad range of high-risk groups.

Published in Osteoporosis International today, ‘The APCO Framework’ comprises 16 minimum clinical standards set to serve as a benchmark for the provision of optimal osteoporosis care in the region.

Developed by APCO members representing key osteoporosis stakeholders, and multiple medical and surgical specialities, this set of clear, concise, relevant and pragmatic clinical standards aims to support national societies, guidelines development authorities, and health care policy makers with the development of new guidelines, and to encourage the revision of existing guidelines.

According to the Framework lead author, APCO Chairperson, and Director of the Osteoporosis and
Bone Metabolism Unit at Singapore General Hospital, Dr Manju Chandran, Singapore, APCO employed a
5IQ analysis and the well-established Delphi Consensus process to analyse the 18 clinical practice guidelines currently available in the Asia Pacific region, to inform the development of The APCO Framework.

“Utilising a comprehensive, four-round Delphi consensus method enabled our APCO members who work in vastly different health care systems, to reach a remarkable level of consensus on a benchmark set of clinical standards for the provision of quality osteoporosis care for the Asia Pacific region.”

The APCO Framework offers clinicians structured, well-articulated, and readily accessible clinical practice guidelines that define:
o Individuals to be identified for assessment;
o Investigations required;
o Relevant indications for treatment;
o Appropriate selection of interventions to be made;
o The guidance and information patients need for self-care;
o Integration of healthcare systems for optimal provision of care; and
o The need, and methods for monitoring and improving the quality of osteoporosis care.

“Implementation of The APCO Framework, or a similar set of standards of care informed by the Framework, is expected to significantly reduce the burden of osteoporosis not only in the Asia Pacific region, but also worldwide. We hope that the Framework can serve as a stimulus for harmonisation of guidelines in other regions that have similar socio-economic diversity and heterogeneity of health care resources,” Dr Chandran said.

Globally, the population aged 65 years or over increased from six per cent in 1990, to nine per cent in 2019.(1)
This proportion is projected to rise to 16 per cent by 2050,(1) meaning one in six people worldwide will be aged
65 years or over by 2050.(1) The number of people aged 60 years and over in the Asia-Pacific region – home to
more than a third of the world’s population aged 65 years and over, and to more elderly people than any other region(2) – is predicted to triple between 2010 and 2050, reaching a staggering 1.3 billion people.(3)

Osteoporotic fractures among Asia-Pacific populations are expected to increase exponentially, not only because of the region’s rapidly aging population, but also due to mounting urbanisation, and the subsequent increase in sedentary lifestyles.(4)

Despite the presence of generally safe and effective treatments for osteoporosis, as many as five in six patients presenting to their primary care physician (PCP), or to a hospital with a fragility fracture, will not be assessed for osteoporosis, nor appropriately managed to prevent further fracture.(5)

According to Medical Director of Osteoporosis Australia, and APCO Executive Committee member,
Professor Peter Ebeling AO, Australia, as many as half of those who have sustained a hip fracture, have already experienced a previous fracture at other skeletal sites.

“In fact, a prior fracture at any site is associated with a doubling of future fracture and mortality risk. The unfortunate ramifications of the gross under-diagnosis and under-treatment of osteoporosis is that a large number of people sustain further debilitating secondary fractures, which places a substantial, but importantly, preventable burden on already strained healthcare systems,” said Prof Ebeling.

A fragility fracture, which occurs every three seconds worldwide,(6) compromises quality of life and loss of independence.(6),(7) Concerningly, one-in-four patients who sustain a hip fracture die within a year, and less than half of those who survive, regain their previous level of function.(8),(9) In 2010, an estimated 158 million people aged
50 years and above were at high risk for osteoporotic fracture – a figure which is set to double by 2040.(10)

According to International Osteoporosis Foundation (IOF) CEO and APCO Executive Committee member,

Dr Philippe Halbout, Switzerland, these alarming statistics, coupled with the anticipated, exponential rise in osteoporotic fractures among Asia-Pacific populations, warrant a standardised set of minimum clinical standards for the region.

“Anecdotal evidence to date reveals significant inconsistencies in osteoporosis clinical practice guidelines in the Asia Pacific region, which vary widely in scope and recommendations. This was confirmed when we analysed the 18 guidelines.

“Implementation of the minimum clinical standards proposed by The APCO Framework, and reform of existing guidelines, will support clinical improvement initiatives, while also paving the way for a more holistic approach to osteoporosis care, and ultimately, greater consistency across all national and regional clinical practice guidelines in the region,” Dr Halbout said.

To download or access The APCO Framework, head to www.apcobonehealth.org/apco-framework

To learn more, visit www.apcobonehealth.org or follow APCO on LinkedIn: asia-pacific-consortium-on-osteoporosis

About APCO

The Asia Pacific Consortium on Osteoporosis (APCO) comprises osteoporosis experts from several countries and regions in the Asia Pacific, charged with developing tangible solutions to the substantive challenges involving osteoporosis management and fracture prevention in this most populated and fastest growing part of the world. APCO’s mission is to engage with relevant stakeholders, including healthcare providers, policy makers and the public, to help develop and implement country and region-specific programs for the prevention and treatment of osteoporosis, and its complication of fragility fractures, in the Asia Pacific.

About IOF

The International Osteoporosis Foundation (IOF) is the world’s largest non-governmental organisation dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF’s mission is to promote bone and musculoskeletal health as a worldwide priority.

The 5IQ analysis and Delphi consensus process

The 5IQ exercise assessed the extent of disparity when comparing the national guidelines currently available throughout the Asia Pacific region.

The Delphi technique (a structured communication technique using a systematic, interactive forecasting method reliant upon an expert panel) was employed to achieve APCO member consensus for the development of clinical standards of care.(11)

EXPERTS AVAILABLE FOR INTERVIEW

Dr Manju Chandran – APCO Executive Committee Chairperson, Senior Consultant, Department of Endocrinology, Director, Osteoporosis & Bone Metabolism Unit, Singapore General Hospital, SINGAPORE

Dr Philippe Halbout – Chief Executive Officer (CEO), International Osteoporosis Foundation (IOF), APCO Executive Committee member, SWITZERLAND

Prof. Peter Ebeling AO – Medical Director, Osteoporosis Australia & APCO Executive Committee member, AUSTRALIA

Dr Zhao Yanling – Obstetrician & Gynaecologist, Beijing United Family Hospital, & APCO Member, Beijing, CHINA

Prof. Atsushi Suzuki – Professor & Chair, Department of Endocrinology & Metabolism, Fujita Health University & APCO Member, JAPAN

Prof. Yoon-Sok Chung – Professor, Department of Endocrinology & Metabolism, Director, Ajou Institute on Aging, Ajou University Medical Center & APCO Member, SOUTH KOREA

Dr Hew Fen Lee – Consultant Endocrinologist, Puchong Medical Specialist Centre, Subang Jaya Medical Centre & APCO member, MALAYSIA

Dato’ Dr. Lee Joon-Kiong – Consultant Orthopaedic Surgeon, Beacon Hospital & APCO Member, MALAYSIA

Dr Nigel Gilchrist – Specialist Consultant Physician, Canterbury District Health Board & APCO ExecutiveCommittee Member, Christchurch, NEW ZEALAND

Mr Paul Mitchell – Adjunct Senior Lecturer, School of Medicine, University of Notre Dame Australia & APCO Executive Committee Member, Auckland, NEW ZEALAND

MEDIA CONTACTS & INTERVIEWS

Kirsten Bruce & Mel Kheradi, VIVA! Communications, Sydney, Australia
T +61 (0)401 717 566; +61 (0)421 551 257
E: kirstenbruce@vivacommunications.com.au; mel@vivacommunications.com.au

DOWNLOAD THE APCO FRAMEWORK DIGITAL MEDIA KIT: www.apcoframeworkmediakit.org


References:
(1) United Nations – Department of Economic and Social Affairs, World Population Ageing 2019 Highlights. 2019.
(2) World Bank Group, Live Long and Prosper – Aging in East Asia and Pacific. 2016.
(3) United National Population Fund (UNFPA) Asia & the Pacific. Ageing. [cited Nov, 2020]; Available from: https://asiapacific.unfpa.org/en/node/15208.
(4) International Osteoporosis Foundation, The Asia-Pacific Regional Audit: Epidemiology, costs & burden of osteoporosis in 2013. 2013. p. 1-128.
(5) Royal Australian College of General Practitioners & Osteoporosis Australia, Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. 2017.
(6) International Osteoporosis Foundation (IOF). Capture the fracture. [cited Jan, 2020]; Available from: https://www.capturethefracture.org/about.
(7) Madureira, M.M., R.M. Ciconelli, and R.M.R. Pereira, Quality of life measurements in patients with osteoporosis and fractures. Clinics (Sao Paulo, Brazil), 2012. 67(11): p. 1315-1320.
(8) National Osteoporosis Foundation, NOF’s Clinician’s Guide to Prevention and Treatment of Osteoporosis.
(9) Australian Institute of Health and Welfare. Musculoskeletal fact sheet. Osteoporosis. [cited Jan, 2020]; Available from: https://bit.ly/3qQOqbi
(10) Oden, A., et al., Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int, 2015. 26(9): p. 2243-8.
(11) Royal College of Obstetricians and Gynaecologists. The Delphi technique. 2005 [cited Jan, 2020]; Available from: https://bit.ly/39hWags



Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Five-minute Covid test will reveal if vaccine still works

Epalinges, Switzerland, Dec 18, 2020 – (ACN Newswire) – Swiss high-tech company ZENUM has developed one of the most advanced technologies in the fight against Covid-19, and it could be ready for distribution as early as next month. The world's first five-minute portable Coronavirus test will also detect how much immunity remains after taking a vaccine.



NANOFLUIDIC RAPID TEST KIT – Identify from a drop of blood whether a person's Covid-19 vaccine is still valid – in 5 Minutes!
ZENUM SWITZERLAND 2021



The game-changing ZEKNANO rapid test kit uses a tiny finger-prick blood sample, instead of swabs. It can be taken anywhere, has close to 100% accuracy, and also measures severity of infection. Thanks to nanotechnology, ZEKNANO not only detects Covid-19 within five minutes, but it identifies up to 14 different conditions simultaneously, including flu virus and infectious diseases.

Artificial Intelligence (AI) is at the heart of the revolutionary product. A neural network – a series of algorithms designed to function like a human brain – has been added to increase the test's efficiency, and study any mutation of the virus.

As the device is portable and lightweight, the tests do not have to be administered only in medical settings. This makes it a leading contender to tackle coronavirus and other diseases in the developing world. It also has the potential to help control the pandemic across all countries before another possible surge in the coming months.

ZENUM already produces 15-minute coronavirus rapid test kits for antibodies and antigens, under the brand ZEKMED. The performance evaluation of these kits were conducted by CIRION Biopharma, one of the few CLIA laboratories in Canada. The results are in accordance with three independent evaluations conducted in Russia, Switzerland and France.

The new ZEKNANO five-minute test is expected to be certified for use in January, putting it ahead of several ongoing projects to achieve such rapid results.

Emidio Do Sacramento, founder and CEO of ZENUM, said: "It doesn't matter if it's a 5 or 15 minute rapid test. Our focus is to help practitioners and health institutions, the best we can, to save lives.

"The reality is that the world is in need of products that solve a problem, and not a marketing sales campaign promoting companies or universities, whether that product is from our company or any other.

"Enough is enough. Mass testing, fast and accurate patient triage is the only reliable solution before any vaccine reaches enough people. We need our lives and economy back to 'normal'."

About ZENUM
ZENUM's origins are rooted in a collaborative network of innovators who strive in the development of applications/mediums/security using biometrics, Ai and blockchain technologies and the infinite influences these technologies will have on life.

As a result of our developments in these fields with our project collaborators and likeminded partners, we found ourselves already engaged and working in the field of medical pre-diagnosis using biometric data for example the research into the pre-diagnosis of glaucoma.

ZENUM is located in new facilities at BIOPOLE, the Life Sciences Campus – one of the largest healthcare research campuses in Europe, and has important medical partnerships in Switzerland, Germany and China. Full technical details can be found at https://zekmed.com/zeknano.html

For more information, please contact:
Emidio Do Sacramento, CEO, Zenum
E: es@zenum.swiss, es@zekmed.com, https://zekmed.com

About the CEO:
https://tinyurl.com/Forbes-Sacramento
https://www.linkedin.com/in/emidiosacramento/
https://www.linkedin.com/company/zenum-technologies/


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Olympus announces acquisition of FH ORTHO, an international orthopedics company in France

Tokyo/Hamburg, Nov 2, 2020 – (ACN Newswire) – Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has acquired FH ORTHO SAS, an international orthopedic company headquartered in Heimsbrunn, France, following the close of a definitive agreement the two companies signed in the summer of 2020. The acquisition underscores Olympus' commitment to expanding in the growing field of orthopedic minimally invasive surgery (MIS) both organically and through mergers and acquisitions, with the overarching goal of developing innovative solutions that improve clinical outcomes, reduce overall costs and enhance quality of life for patients.

By acquiring FH ORTHO, Olympus builds on its portfolio of innovative and patient-focused solutions that are used in MIS procedures in ligament repair, foot & ankle, and trauma surgery.

Olympus is already active in orthopedics in Japan, where its joint venture Olympus Terumo Biomaterials Corp. distributes products such as bone substitutes and high tibial osteotomy (HTO) plates and screws. Beyond this, Olympus has also developed the first ultrasound device indicated for arthroscopic surgery, supporting more accurate and safer cutting of bones.

The acquisition of FH ORTHO will strengthen Olympus group's sales channels by enabling it to expand the distribution of both Olympus' orthopedic products via FH ORTHO's existing distribution channels, as well as to sell certain FH ORTHO key products in Japan.

By expanding its distribution network, Olympus will reinforce its position as a leading global medtech company as it continues to innovate and create solutions across all areas of the MIS workflow.

"We are pleased to integrate FH ORTHO's product portfolio, market reach and talented people to our orthopedics business," says Toshihiko Okubo, Senior Vice President, New Business Development, Global at Olympus. "By combining FH ORTHO's expertise and its excellent business presence with our products and solutions for the minimally invasive orthopedics surgery, the benefit of our offer to the patients and healthcare professionals will be further enhanced across the world."

Jean-Marc Idier, CEO of FH ORTHO, comments, "The FH ORTHO team very positively welcomes the arrival of Olympus as a recognition of our ongoing efforts and past accomplishments, whilst providing us with new means to accelerate the next phase of our international expansion."

About FH ORTHO

FH ORTHO develops and manufactures orthopedic devices and instruments for surgeons around the world. Founded in Mulhouse, France in 1964, FH ORTHO is represented in over 37 countries, with products focused on joint reconstruction, ligament repair, biologics, foot & ankle, and trauma surgery. R&D and factory are based in Quimper, France. Backed by 55 years of forward-thinking innovation in devices, techniques and product delivery, the company today is positioned for rapid expansion globally.

With an unrelenting commitment to innovation, research and collaboration, FH ORTHO continues to bring new ideas and techniques to advance the forefront of orthopedics globally. FH ORTHO products are developed and refined by surgeon experts who are among the world leaders in their respective fields. Prized for elegant design and distinguished by clinical sophistication and flexibility, FH ORTHO products help surgeons deliver ideal patient outcomes with devices, systems and tools that simplifies patient management for the surgeon, at an overall cost structure that is a benefit to the entire patient continuum of care.

About Olympus' Medical business

Olympus' Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.

For questions or additional information, please contact:
Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com

Japan
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com